Hyung Cho, MD
Ophthalmology · Atlanta, GANPI 1265737415
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (49.4%), ownership interests and consulting fees — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by US Retina LLC at 27.3% of the total. Reporting peaked in 2019 at $5,307 and has fallen 73.2% since, to $1,422 in 2025. Among ophthalmology clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 316 payments — averaging $66.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$6K
- Alimera Sciences, Inc.$5K
- Genentech USA, Inc.$3K
- Regeneron Healthcare Solutions, Inc.$3K
- AbbVie$826
- Astellas Pharma US Inc$716
- plus $3K from 15 others
Across 4 payments — averaging $37.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Notal Vision, Inc.$150
What the payments were for
- Consulting fees$3,00014%
- Speaking & faculty fees$1,8799%
- Food & beverage$10,35349%
- Ownership interest$5,72327%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 6 | $5,723 |
| Alimera Sciences, Inc. | 32 | $5,130 |
| Genentech USA, Inc. | 78 | $2,839 |
| Regeneron Healthcare Solutions, Inc. | 88 | $2,726 |
| AbbVie(2 entities) | 31 | $826 |
| Astellas Pharma US Inc | 22 | $716 |
| Notal Vision, Inc. | 3 | $679 |
| Apellis Pharmaceuticals, Inc. | 12 | $492 |
| ANI Pharmaceuticals, Inc. | 6 | $437 |
| Novartis | 11 | $293 |
| Alcon | 2 | $265 |
| Bausch & Lomb Americas Inc. | 4 | $213 |
| Regeneron | 1 | $123 |
| Pfizer | 1 | $112 |
| Eyepoint US, Inc. | 6 | $102 |
| Coherus Oncology, Inc. | 4 | $83 |
| Mallinckrodt Enterprises LLC | 3 | $70 |
| NEW World Medical,inc. | 3 | $46 |
| Sandoz | 1 | $38 |
| Halozyme Inc | 1 | $25 |
| Dutch Ophthalmic, USA | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,956 in reported general payments places this provider in the 90th percentile of 481 ophthalmology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 73 | $3,002 |
| Brimonidine Tartrate | 12 | $1,037 |
| Timolol Maleate | 61 | $605 |
| Latanoprost | 66 | $563 |
| Atropine Sulfate | 18 | $409 |
| Ketorolac Tromethamine | 15 | $371 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 27 | $354 |
| Ciprofloxacin Hcl | 31 | $269 |
| Cyclopentolate Hcl | 12 | $123 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Atlanta
- Gagan SawhneyAtlanta$582K
- Lawrence WoodardAtlanta$578K
- Stephanie VanderveldtAtlanta$384K
- Steven YehAtlanta$289K
- Evan SchoenbergAtlanta$130K
- Robert StultingAtlanta$85K
- David SackelAtlanta$82K
- Atul SharmaAtlanta$77K
- Daniel MartinAtlanta$55K
- Douglas DayAtlanta$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.